Status:

COMPLETED

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Lead Sponsor:

Pfizer

Conditions:

Tick-borne Encephalitis

Eligibility:

All Genders

6-15 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.

Eligibility Criteria

Inclusion

  • Male and female children will be eligible for participation in this study if:
  • they are 6 years (from the 6th birthday) to 16 years old (to the last day before the 16th birthday);
  • they are clinically healthy;
  • their legal representative - and if older than 8 years the volunteer - understands the nature of the study, agrees to its provisions and gives written informed consent;
  • their legal representative agrees to keep a Volunteer Diary.
  • For safety reasons female volunteers capable of bearing children have to fulfill the following inclusion criteria at study start:
  • negative pregnancy test at study start;
  • they agree to employ adequate birth control measures for the duration of the study.

Exclusion

  • Children will be excluded from participation in this study if they:
  • have a history of any previous TBE vaccination;
  • have a history of TBE infection or show evidence of a latent TBE infection (as demonstrated by screening ELISA \> 126 VIEU/ml and / or neutralization test \> 1:10);
  • have a history of allergic reactions, in particular to one of the components of the vaccine;
  • have received antipyretics within 4 hours prior to the first TBE vaccination;
  • suffer from a disease that cannot be effectively treated or stabilized;
  • suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment that can be expected to influence immunological functions;
  • suffer from chronic, degenerative and / or inflammatory disease of the central nervous system;
  • are known to be HIV positive (a special HIV test is not required for the purpose of the study);
  • suffer from a febrile illness at study entry;
  • have a history of vaccination against yellow fever and / or Japanese B-encephalitis;
  • are participating simultaneously in another clinical trial.
  • if female, are pregnant or breast feeding
  • Volunteers who meet the inclusion / exclusion criteria, but have a febrile illness (body temperature \>= 38° C, measured orally) at the scheduled time of vaccination, will not be vaccinated before their body temperature returns to normal.

Key Trial Info

Start Date :

September 1 2001

Trial Type :

INTERVENTIONAL

End Date :

March 1 2002

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00161798

Start Date

September 1 2001

End Date

March 1 2002

Last Update

May 21 2015

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Neuschwansteinstrasse 5

Augsburg, Germany, 86163

2

Marktplatz 33

Bad Saulgau, Germany, 88348

3

Hauptstrasse 9

Bietigheim-Bissingen, Germany, 74321

4

Salzgasse 11

Calw, Germany, 75365